Introduction
Myocyte enhancer factor-2 (MEF2) was originally identified as a muscle-specific DNA-binding activity that was induced when skeletal myoblasts differentiated into myotubes (Gossett etal., 1989; reviewed by Olson et al., 1995) . The MEF2-binding site, CTA(A/T)4TAG, is found in thecontrol regions of numerous muscle-specific genes and has been demonstrated to be important for skeletal and cardiac muscle gene expression (Olson et al., 1995 and references therein) . MEFP DNA-binding activity is encoded by four genes in humans and mice, referred to as mef2A through mef2D (Pollock and Treisman, 1991; Yu et al., 1992; Breitbart et al., 1993; Martin et al., 1994) whose products bind DNA as homodimers and heterodimers. MEF2 proteins contain a 56 amino acid MADS domain, named for the first four proteins in which this domain was identified: minichromosome maintenance 1 (MCMl), which regulates mating-specific genes in yeast, AGA-MOUS and DEFICIENS, which have homeotic functions in flower development, and serum response factor (SRF), which regulates serum-inducible and muscle gene expression (reviewed by Shore and Sharrocks, 1995) . The four mef2 gene products, also referred to as RSRFs (for related to SRFs) (Pollock and Treisman, 1991) , share greater than 85% amino acid identity within the MADS domain and an adjacent 27 amino acid region referred to as the MEF2 domain, but they are divergent in their C-termini. This ho- mology in the MADS and MEF2 domains is also observed in the single MEF2 protein in Drosophila (Lilly et al., 1994; Nguyen et al., 1994; Taylor et al., 1995) and several MEF2 proteins in Xenopus (Chambers et al., 1992; Wong et al., 1994) .
Expression of the mef2 genes marks early myogenic lineages during embryogenesis (Edmondson et al., 1994; Chambers et al., 1992) . MEF2C is the first member of the family to be expressed in the mouse, with transcripts appearing in the precardiac mesoderm at day 7.5 postcoiturn (PC). Subsequently, the other mef2 genes are expressed throughout the developing heart. MEF2C is expressed in skeletal muscle cells within the somite myotome beginning at about day 9.0 pc, and the other mef2 genes are expressed soon thereafter. The mef2 genes also show specific expression patterns in the developing brain (Lyons et al., 1995) . After birth, MEF2A, MEF2B, and MEF2D transcripts are expressed ubiquitously (Pollock and Treisman, 1991; Yu et al., 1992; Leifer et al., 1993; Martin et al., 1993 Martin et al., , 1994 McDermott et al., 1993; Breitbart et al., 1993) , whereas MEFPC transcripts are restricted to skeletal muscle, brain, and spleen (Martin et al., 1993; McDermott et al., 1993) . Despite the widespread expression of mef2 mRNAs in adult tissues and established cell lines, MEF2 DNA-binding activity is highly enriched in muscle cells and neurons.
Recent evidence suggests that MEF2 and myogenic basic-helix-loop-helix (bHLH) proteins act within a regulatory network that establishes the differentiated phenotype of skeletal muscle. The four myogenic bHLH proteins, MyoD, myogenin, myf5, and MRM, can each activate the program for skeletal muscle differentiation when introduced into a variety of nonmuscle cell types (Olson, 1990; Emerson, 1993; Wright, 1992; Lassar and Munsterberg, 1994) . The bHLH motif mediates dimerization of the myogenie factors with ubiquitous HLH proteins such as E12, E47, and HEB, resulting in heterodimeric complexes that bind to the E box consensus DNA sequence (CANNTG) (Murre et al., 1989; Brennan and Olson, 1990; Lassar et al., 1991; Hu et al., 1992 ) associated with many musclespecific genes. Paradoxically, however, myogenic bHLH proteins can also activate transcription of muscle-specific genes that lack E boxes in their control regions. The mechanism responsible for this type of indirect gene activation by myogenic bHLH proteins has not been clarified.
Forced expression of myogenin or MyoD in nonmuscle cells induces MEF2 DNA-binding activity, suggesting that MEF2 lies within a regulatory cascade downstream of the myogenic bHLH proteins (Martin et al., 1993; Chambers et al., 1994; Cserjesi and Olson, 1991; Lassar et al., 1991) . However, a MEF2 site within the myogenin promoter has been shown to be essential for myogenin transcription in cultured muscle cells and mouse embryos (Edmondson et al., 1992; Cheng et al., 1993; Yee and Rigby, 1993) . Similarly, the Xenopus myoDa gene is regulated by a MEF2 site that overlaps with the TATA box (Leibham et al., 1994) . Forced expression of MEF2A in fibroblasts has also been reported to induce the expression of myogenin Cultures were transferredfromgrowthmedium(GM)2daysaftertransfectiontodiffer-entiation medium (DM) for an additional 6 days and were then stained with Hoechst (A-F), anti-MHC (A-H), or anti-MEFPC (G and H) . No MHC staining was observed with MEFPC or with the bHLH region of myogenin (Myo-bHLH) alone. Note the presence of MEF2C in the nuclei of cells that did not express MHC (G), unless MyoD was also present (H).
and MyoD and to initiate muscle differentiation (Kaushal et al., 1994) . Together, these data suggest that MEF2 and myogenic bHLH proteins are involved in reciprocal regulatory circuits that amplify and maintain the expression of both families of regulators.
The functions of vertebrate MEF2 factors have not yet been analyzed by loss-of-function assays. However, lossof-function mutations in the single mef2gene in Drosophila prevent differentiation of somatic, cardiac, and visceral musclecells (Lillyet al., 1995; Bour et al., 1995; Ranganayakulu et al., 1995) , demonstrating that MEF2 is necessary for the differentiation of multiple muscle cell types. The MyoD homolog Nautilus (Michelson et al., 1990; Paterson et al., 1991) appears in myoblasts within the somatic muscle lineage in D-men mutant embryos, but it is unable to activate the expression of muscle structural genes, suggesting that D-MEFP is required for Nautilus activity.
In this study, we demonstrate that MEF2 factors act as coregulators to potentiate the myogenic activities of myogenic bHLH proteins. This cooperativity requires inter- action between the DNA-binding domains (DBDs) of MEF2 and myogenic bHLH factors, which allows these two classes of transcription factors to activate synergistically the transcription of genes containing a binding site for only one of the two factors.
Results

MEFSC Synergizes with Myogenic bHLH Factors to Induce Myogenesis
To begin to define the role of MEF2 in muscle-specific gene activation, we tested whether forced expression of MEF2C was sufficient to induce myogenesis in transfected lOTI/ cells. In contrast with a previous report (Kaushal et al., 1994) Table 1 ). Under these conditions, we observed a 3-to 4-fold increase in the number of MHC-positive ceils. We also observed a substantial increase in the number of multinucleate myotubes that were present, whereas with either myogenic bHLH factor alone the majority of MHCpositive cells were mononucleate ( Figure 1 ; Table 1 ). Like MEFPC, MEF2A and MEF2D were unable to induce myogenesis alone, but cooperated with MyoD to induce myogenesis (Table 1 ). The magnitude of the synergism between MEF2 and myogenic bHLH proteins is probably underestimated in these assays, because in the presence of MEF2 most of the MHC-positive cells were multinucleate myotubes, which were scored as single positive cells.
To quantitate further the magnitude of the synergism between myogenic bHLH proteins and MEF2, we measured MHC protein expression by Western blot analysis of extracts from transiently transfected 1OTM cells ( Figure  2 ). MEF2C alone was unable to induce MHC expression, whereas, in the presence of myogenin or MyoD, MHC protein was induced to a level about 8-to lo-fold higher than with either myogenic bHLH factor alone.
Synergism between MEF2 and Myogenic bHLH Factors Is Mediated by Their DBDs To begin to define the region within the myogenic bHLH factors that cooperates with MEF2, we tested the ability of a myogenin mutant (Myo-bHLH) lacking the N-and C-terminal activation domains to induce myogenesis with MEF2C. This mutant dimerizes with E proteins and binds DNA, but it lacks myogenic activity (Schwarz et al., 1992 Figure 3A) , which lacks the C-terminal transactivation domain and is unable to activate a MEF2-dependent reporter, cooperated with the myogenic bHLH factors to initiate myogenesis, but it was slightly weaker than the wild-type protein (Table 1) suggesting that the transcriptional activation domain enhanced the synergism, but was dispensable. We observed no myogenic conversion when mutant l-l 17 was expressed together with the myogenin deletion mutant MyobHLH, indicating that one of the two factors needed an activation domain. The mutant l-l 17-VP16, in which the transcription activation domain of MEF2C was replaced with that of herpesvirus virion protein 16 (VP16) ( Figure  3A ), was unable to induce myogenesis independently, but showed stronger synergistic activity than wild-type MEF2C (Table 1) . Together, these results demonstrate that MEF2 is a cofactor for myogenic bHLH proteins and that a transcriptional activation domain is required in either MEF2 or a myogenic bHLH protein, but not in both, to activate endogenous muscle-specific genes in 1 OTX cells.
To determine whether DNA binding by MEF2C was required for synergism with myogenic bHLH factors, we examined the activity of two MEF2C mutants, R24L and K31 L, which contain point mutations in the MADS domain and fail to bind DNA (Figure 38 ; J. D. M. and E. N. O., unpublished data). Surprisingly, both of these mutants were able to cooperate with MyoD and myogenin to induce myogenesis (Figure 1 F; Table 1 ). We further defined the region within the N-terminus of MEF2C that mediates synergism with myogenic bHLH factors by testing two MEF2C deletion mutants, A40-57 and A58-85, which lack portions of the MADS box and MEF2 domains and are unable todimerizeor bind DNA(J. D. M. and E. N. O., unpublished data). Both of these mutants failed to increase the expression of MHC over that induced by myogenin or MyoD alone. Together, these results suggest that the MADS and MEF2 domains are required for cooperativity between MEF2C and myogenic bHLH factors, but DNA binding and transcriptional activation by MEF2C are not required. Because SRF has been implicated in muscle gene activation (Walsh, 1989; Sartorelli et al., 1990; Lee et al., 1992) , we tested whether it might also synergize with MyoD to induce myogenesis. When SRF was coexpressed with MyoD, however, we observed no increase in MHCpositive cells over the number seen with myogenin alone (Table 1) . Thus, although SRF and MEF2 share homology in their MADS domains, this homology is insufficient to mediate synergism between SRF and the myogenic factors in a myogenic conversion assay.
Because synergism between myogenic bHLH factors and MEF2C did not require DNA binding by MEF2C, we tested whether a myogenin mutant that was unable to bind DNA might be able to synergize with MEF2C ( Previous studies demonstrated that two amino acids, alanine-threonine, in the center of the DBDs of myogenic bHLH proteins were required for muscle gene activation (Davis et al., 1990; Brennan et al., 1991) . If these residues were replaced with asparagines, which are found at the corresponding positions in the DBDs of E proteins, the mutant myogenic factors retained the ability to bind DNA, but they lost the ability to activate myogenesis. Conversely, if alanine and threonine were introduced into the corresponding positions of E12, they conferred on El2 the ability to activate muscle gene expression (Davis and Weintraub, 1992) . Because these myogenic amino acids do not affect DNA binding but are essential for myogenic activity, it has been hypothesized that they mediate interaction with a cofactor required for muscle gene activation (Davis et al., 1990; Brennan et al., 1991; Weintraub et al., 1991) . To determine whether these same myogenic amino acids were required for cooperativity with MEF2, we tested whether the mutant MyoD-El2basic, which contains the basic region of El2 in place of that of MyoD, could synergize with MEF2 to activate myogenesis. In contrast with wild-type MyoD, this mutant failed to synergize with MEF2C (Table 1) . However, if alanine-threonine was reintroduced into the El2 basic region in the mutant MyoDEl 2(AT), which has been shown to restore myogenic activity to MyoD (Davis and Weintraub, 1992) the ability to synergize with MEF2 was also restored (Table 1 ). These results demonstrate that the myogenic amino acids in the DBD of MyoD are required for cooperativity with MEF2.
Interaction between MEFSC and MyogeninlEl2
Heterodimers To investigate further the basis for the cooperation between MEF2 and myogenic bHLH proteins, we tested whether these proteins physically interacted. Myogenin and El 2 were translated in a rabbit reticulocyte lysate separatelyand in conjunction with the MEF2C deletion mutant l-105, which contained a Flag epitope tag. 35S-labeled translation products were then immunoprecipitated with an anti-Flag antibody and resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). When MEF2C was cotranslated with either myogenin or E12, there was no evidence for protein-protein interactions (Figure 4 , lanes 6 and 7). However, when MEF2C was cotranslated with myogenin and E12, both bHLH proteins were coimmunoprecipitated with MEFC ( Figure 4 , lane 5). These results demonstrate that MEF2 binds specifically to the myogeninlE12 heterodimer, but not to myogenin or El2 homodimers.
Mapping of Interactions of MEFSC and MyogeninlElS
Using a Tri-Hybrid System To determine whether MEFPC interacted with myogenin/ El2 heterodimers in vivo and to map the domains of MEF2C that mediated this interaction, we employed a GAL4 DBD-dependent reporter system, in which the bHLH regions of myogenin and El2 were fused to the DBD of yeastGAL4(Figure5A). When introduced into lOTI/ cells, these chimeric proteins, referred to as GAL(DBD)-Myo and GAL(DBD)-E12, failed to activate expression of the GAL4-dependent reporter gene pG5El bCAT ( Figure 58 , lanes 1 and 4). When GAL(DBD)-Myo was expressed with El 2, chloramphenicol acetyltransferase (CAT) expression was induced as a result of heterodimerization between the bHLH of myogenin and that of El2 (lane 6). The El2 expression plasmid used for these experiments encoded an El 2 deletion mutant lacking part of the N-terminal transcription activation domain and therefore results in only weak transactivation. We used this mutant so that interactions with MEMC could be more readily detected above the transcriptional activity of GAL(DBD)-Myo plus El2 (see below). If full-length El2 was coexpressed with GAL(DBD)-Myo, much higher activation was observed (Chakraborty et al., 1992) . We detected no expression of the reporter gene when either GAL(DBD)-Myo or GAL(DBD)-El2 was coexpressed separately with MEFPC ( Figure 58, lanes 3 and 5) . However, if GAL(DBD)-Myo and El2 were expressed together with MEFPC, there was an -g-fold increase in reporter gene expression over the level seen without MEF2C (Figure 58, lane 7) . In contrast, MEF2C did not enhance reporter gene expression in the presenceofGAL(DBD)-E12andEl2(Figure5B,lane3)or in the presence of GAL(DBD)-Myo (lane 5). These results suggested that MEFPC was able to interact in vivo, specifically with the myogeninlE12 heterodimer and not with an E12/E12 homodimer or with myogenin alone.
To map the region of MEF2C that was required for interaction with myogenin/E12, we tested several MEF2C mutants in the above assay. The deletion mutant l-l 17 demonstrated the ability to interact with myogeninlE12, although the magnitudeof activation wasless than with the full-length protein (Figure 58, lane 8) . This is presumably because mutant l-l 17 lacks an activation domain. However, it retains the ability to dimerize and may recruit the low level of endogenous MEFP protein in 1 OT% cells. Alternatively, there may be an additional cofactor that recognizes the complex of MEF2-myogenin/E12.
Fusion of the VP16 activation domain to MEF2C l-l 17, to create l-l 17-VP16, resulted in greater than 35fold activation of the reporter ( Figure 5B, lane 9) . If El2 was omitted from the assay, l-l 17-VP16 only weakly interacted with GAL(DBD)-Myo ( Figure 5B , lane 10). This weak activation probably occurs because of the low level of endogenous E proteins in lOT% cells that dimerize with GAL(DBD)-Myo. Deletion of the MEF2 domain in mutants A58-85 and A70-85 severely diminished interaction of MEF2C with myogeninlE12
( Figure 5C , lanes 4 and 5). Similarly, the mutant A40-57, which lacked part of the MADS box, interacted with myogeninlE12 less effectively than wildtype MEFPC ( Figure 5C, lane 3) .
The above results demonstrated that the determinants of the interaction between MEF2C and myogeninlE12 were located within both the MADS and MEFP domains of MEF2C. To define further the residues that mediated this interaction, we tested several MEF2 site-directed mutants in thisassay. Mutation of Lys31, which had a minimal effect on synergism between MyoD and MEF2C in myogenie conversion (Table l) , also had only a minimal effect on interaction with GAL(DBD)-Myo plus El 2 ( Figure 5C , lane 6). We tested 12 separate point mutants of the MADS box in the tri-hybrid assay, yet no single mutation led to a loss in the ability of MEF2C to interact with myogeninl El 2 (data not shown). These data suggest that the interactive surface is distributed throughout the MADS box of MEF2C. The interaction between MEF2C and myogeninl El2 did not require MEF2 DNA-binding activity, since mutant STDMD59-63, which dimerized but failed to bind DNA, interacted with myogeninlE12 as effectively as the wild-type protein ( Figure 5C , lane 8). We also introduced mutations into the MEFP domain to map the amino acids that were required for interaction with myogeninlE12.
Mutants STDMD59-63 and VLL65-67, containing mutations toward the N-terminal end of the MEF2 domain, interacted with myogeninlEl2 as efficiently as wild-type MEF2C (Figure 5C, lanes 8 and 9) , whereas the more C-terminal mutants NEPH73-76 and ESRT77-80 did not interact (lanes 10 and 11). suggesting that the C-terminal end of the MEF2 domain plays a major role in mediating interaction between MEFPC and myogeninlE12. The above experiments demonstrated that MEFP was able to interact directly with myogeninlE12 heterodimers and that synergism between MEF2 and myogenic bHLH proteins did not require direct binding of MEFP to DNA. To Fold-Activation determine whether MEF2 was able to synergize with myogenin to activate transcription through the E box-binding site, we tested whether the myogenin mutant Myo-bHLH could cooperate with MEF2 to transactivate the E boxdependent reporter 41%TKCAT, which contains four tandem copies of the right E box from the muscle creatine kinase (MCK) enhancer upstream of the thymidine kinase (TK) promoter linked to CAT (Weintraub et al., 1990) . This reporter does not respond to MEF2 or the highly potent MEM mutant l-l 17-VP16, confirming that it contains no MEF2-binding sites ( Figure 6A , lane 8). Myo-bHLH was also unable to activate expression of 41%TKCAT because this mutant lacks the N-and C-terminal transactivation domains ( Figure 6A, lane 3) . Similarly, an N-terminal deletion mutant of El2 lacking the transcription activation do- s main was unable to activate this reporter alone or in the presence of Myo-bHLH ( Figure 6A, lanes 2 and 4) . However, a high level of transactivation was observed when the three factors, Myo-bHLH, E12, and MEF2C, were combined ( Figure 6A, lane 9) . This transactivation was dependent on the E boxes in the reporter gene because the TK promoter alone was nonresponsive (data not shown). Transcriptional activation was also dependent on all three factors; any two of the factors showed no transcriptional activity( Figure 6A, lanes4,6, and 7) . The MEF2 mutant, K31 L, which was unable to bind DNA, synergized with Myo-bHLH plus El2 as efficiently as wild-type MEF2 ( Figure 6A, lane CAT( Figure 6A, lane2) , which contains two tandem copies of the MEF2 site from the MCK enhancer upstream of the embryonic MHC basal promoter ( Figure  6B ). As was the case for the E box-dependent reporter, any combination of two factors was unable to activate the MEFP-dependent reporter ( Figure  6B , lanes 3-5). However, when myogenin plus El2 was expressed with the DBD of MEF2C, which lacks transcriptional activity on its own, the reporter gene was activated to high levels ( Figure  6B , lane 6). results demonstrate that myogenic bHLH proteins can induce transcription of a gene lacking an E box by transferring activation to the DBD of MEF2 when it is bound to its site.
Finally, we tested the MyoD mutant, MyoD-E12basic containing the El2 basic region to determine whether it could synergize with MEF2 mutant l-l 17 to activate transcription through the MEF2 site. Despite the fact that this MyoD mutant containsafunctional transcription activation domain (Weintraub et al., 1991) , it was unable to transfer its activating potential through MEF2 to activate the MEF2-dependent reporter( Figure  6B , lane7). However, introduction of the myogenic amino acids, alanine-threonine, into the DBD of this mutant restored the ability to cooperate with the DBD of MEF2 to activate transcription (MyoD-E12(AT) in Figure 6B, lane 8) . Thus, the same residues in the MyoD basic region that are required for activation of the myogenic program are required for MyoD-mediated activation of transcription through the MEF2 site.
Discussion
The results of this study demonstrate that MEF2 factors collaborate with myogenic bHLH proteins to activate mus-cle gene expression and that this cooperativity is mediated by direct protein-protein interactions between the DBDs of these heterologous classes of transcription factors. This type of cooperativity provides an explanation for the absence of muscle in Drosophila embryos lacking MEFP and for previous mutational analyses of the basic regions of myogenic bHLH factors, which suggested that they required a cofactor that recognized the DBD for activation of myogenesis.
Synergy between MEF2 and Myogenic bHLH Proteins Is Mediated by Interactions between Their DBDs
Our initial observation was that MEF2 factors alone were incapable of initiating the myogenic program in transfected lOT% cells, but that MEFPA, MEF2C or MEF2D could augment the myogenic activity of MyoD or myogenin. These results differ from those of a previous study, which reported that MEF2A wasa myogenicdetermination factor that could induce the complete myogenic program in transfected fibroblasts with an efficiency comparable with that of MyoD (Kaushal et al., 1994) . We have been unable to detect expression of muscle structural genes or the formation of multinucleate myotubes following transient or stable transfection of lOT% cells with MEF2A, MEFPC, or MEF2D, even when using the same expression plasmid used by Kaushal and coworkers. The basis for the discrepancy between the two studies is unclear.
The synergy between MEF2 and myogenic bHLH proteins suggested that these factors physically interacted. Indeed, coimmunoprecipitation and tri-hybrid assays demonstrated that MEF2 recognized myogeninlE12 heterodimers. Only when all three proteins were present together was a physical interaction apparent. These analyses demonstrated that the MADSlMEFP domains of MEF2C specifically interacted with the heterodimer formed between the bHLH regions of myogenin and El2 and demonstrated aprecisecorrelation between the ability of MEF2 mutants to interact with myogeninlE12 in vivo and their ability to cooperate in myogenic conversion. This is consistent with previous studies that showed that MEF2 binds DNA cooperatively with myogenin in myotube nuclear extracts (Funk and Wright, 1992) . A previous study in which interactions between MyoD and MEF2 were analyzed using GST fusion proteins (Kaushal et al., 1994) concluded that only the MADS domain was sufficient for interaction with MyoD and that El 2 was not necessary for the interaction.
MEF2 and Myogenic bHLH Factors Cross-Activate through Each Other's Binding Sites A myogenin mutant containing only the bHLH region was unable to activate the E box-dependent reporter in the presence of a truncated El2 protein. However, when wildtype MEFPC containing an intact transactivation domain was expressed with the bHLH regions of myogenin and E12, synergistic activation of transcription was observed. Furthermore, a mutant MEF2C protein (K31L) that was incapable of binding DNA by itself was still able to interact with the Myo-bHLHIE12 heterodimerto activate transcription synergistically through the E box. MEF2C expressed separately with the bHLH regions of either myogenin or El2 was unable to potentiate transcription through the E box. Together, these results suggest that the heterodimer of Myo-bHLHIEl2 binds to the multimerized E box sites to act as a platform on which MEF2C interacts to activate transcription.
A MEFPC deletion mutant lacking a transactivation domain was unable to activate transcription through the MEF2 site by itself or with either El2 or myogenin alone. Onlythecombinationof MEF2C l-l 17 and myogeninlE12 together resulted in transcriptional activation, demonstrating that the heterodimer of myogeninlE12 could interact with MEF2 bound to DNA. These results provide an explanation for previous studies that demonstrated that MEF2 and myogenic bHLH factors synergistically activate transcription of muscle gene promoters containing binding sites for only one of the factors (Naidu et al., 1995; Black et al., 1995) .
The model generated from these in vitro expression experiments is supported by the in vivo results using the myogenic conversion assay. In this assay, the bHLH region of myogenin by itself is unable to induce myogenesis. However, when wild-type MEF2C containing a transactivation domain is expressed with the myogenin bHLH, myogenie conversion is restored. This suggests that, in vivo, MEFPC can specifically interact with the myogenin bHLH domain at E box target sites to activate transcription by protein-protein association and the recruitment of the transactivation domain of MEF2C. This also suggests that an activation domain is required in only one component of the complex between MEF2 and myogenic bHLH proteins for the myogenic program to be executed.
When tested in the myogenic conversion assay, MyoD and MEF2 synergized to activate myogenesis without the need for exogenous E proteins. Previous studies demonstrated that E proteins are required for MyoD function and that the level of endogenous E proteins in IOTX cells is sufficient to support myogenic conversion (Lassar et al., 1991) . In contrast, when MyoD and MEF2 were tested for their ability to synergize on artificial reporters, it was essential that exogenous El2 also be provided. These results suggest that E proteins are limiting for activation of exogenous reporter genes that are present at high copy number.
Multiple Mechanisms for Muscle Gene Activation by MEF2 and Myogenic bHLH Factors
Our results demonstrate that MEF2 and myogenic bHLH factors can transfer transcriptional activity through one another's DBDs when only one of the two factors is bound directly to DNA. Thus, the DBDs of MEF2 and myogenic bHLH factors play dual roles in the control of muscle gene transcription by mediating DNA sequence recognition and protein-protein interactions. The DBDs of MEF2 and myogenie bHLH factors are also able to discriminate among different members of each class of transactivators.
The interaction between MEF2 and the myogenic bHLH proteins requires only the bHLH domain, and myogenic conversion by the trimeric complexes was dependent on the two myogenic amino acids, alanine-threonine, in the basic region of MyoD. It has been hypothesized that these amino acids mediate interaction with a coregulator required for muscle gene activation (Davis et al., 1990; Brennan et al., 1991; Davis and Weintraub, 1992) . Our results are consistent with the possibility that MEF2 is an essential coregulator through which the myogenic bHLH factors induce muscle gene transcription. The crystal structure of MyoD bound to DNA indicates that the myogenic residues in the MyoD basic region lie within the major groove of the DNA and are thus inaccessible for direct interaction with MEF2 (Ma et al., 1994) . However, these residues appear to be required for a conformational change in MyoD that may create the recognition surface for MEF2 interaction.
Further evidence implicating MEF2 asan essential coregulator of muscle gene expression has been demonstrated by genetic analyses of mef2 in Drosophila (Lilly et al., 1995; Bour et al., 1995; Ranganayakulu et al., 1995) . Loss-of-function mutations of Dmef2 prevent muscle cell differentiation, but they do not affect myoblast specification. In D-mef2 mutant flies, the myoD homolog nautilus is expressed normally in somatic muscle cell precursors, but muscle structural genes are not expressed. Thus, D-MEF2 may be essential for Nautilus function in somatic muscle cells.
Together, our results support the model for MEF2 regulation of muscle genes shown in Figure 7 . According to this model, MEF2 factors act as coregulators that mediate the myogenic activity of myogenic bHLH proteins. Assuming this to be the case, there would need to be MEF2 activity in nonmyogenic cells in which the myogenic bHLH proteins can induce myogenesis. In fact, the existence of MEF2 factors in lOT% and other nonmyogenic cell types has been documented (Pollock and Treisman, 1991; Buchberger et al., 1994) . There is also a low level of MEFPD protein in myoblasts that could collaborate with myogenic bHLH proteins to initiate the differentiation program (Breitbart et al., 1993) . Previous studies have demonstrated that myogenic bHLH proteins can induce MEF2 expression (Cserjesi and Olson, 1991; Lassar et al., 1991; Martin et al., 1993) which would further amplify muscle gene expression once the program has been initiated. Binding of MEF2 to the promoters of myogenic bHLH genes would also result in amplification and maintenance of their expression (Edmondson et al., 1992; Cheng et al., 1993; Yee and Rigby, 1993; Leibham et al., 1994; Black et al., 1995; Naidu et al., 1995) . MEFP can also activate E box-independent target genes by binding directly to MEF2 sites in the control regions of those genes. In these cases, myogenic bHLH proteins could also activate these genes through protein-protein interactions with MEF2. In addition, MEF2 can collaborate with myogenic bHLH proteins to activate expression of genes that are controlled by E boxes and MEF2 sites or it can act through myogenic bHLH proteins to activate E box-dependent genes that lack MEF2 sites. MEFP binds the control regions of several myogenic bHLH genes, amplifying and maintaining their expression.
Myogenic bHLH proteins activate E box-dependent genes that also contain MEF2 sites. MEF2 can also act indirectly to activate E box-dependent genes by interacting with myogenic bHLH proteins. MEF2 can regulate muscle genes that lack E boxes in their control regions; MyoDlElP heterodimers may also activate these genes by protein-protein mteractions with MEFP. Interactions between MEFP and MyoD/EiZ may also provide a mechanism for linking muscle-specific promoters and enhancers Our demonstration that myogenic bHLH factors can activate transcription through the MEF2 site by interacting with the DBD of MEF2 may explain how myogenic bHLH factors induce the expression of muscle-specific genes that lack E boxes in their control regions. It is also interesting to point out that several muscle-specific genes appear to contain MEF2 sites embedded within their TATA boxes (Leibham et al., 1994; Grayson et al., 1995) . Thus, binding of MEF2 to these elements may recruit myogenic bHLH factors to the promoters (Figure 7 ). This type of recruitment may provide a general mechanism for enhancer-promoter communication through which transcription factors at a distal enhancer are brought into contact with the promoter by interaction with heterologous transcription factors bound at or near the TATA box.
How do the interactions between myogenic bHLH and MEF2 factors result in synergistic activation of muscle gene expression? As discussed above, previous mutational analyses provided strong evidence for the existence of a factor that recognized, and conferred myogenic activity to, the basic regions of myogenic bHLH proteins. Based on our results, we propose that MEF2 is this factor and that it recognizes the bHLH regions of myogenic bHLH proteins when they are dimerized with E proteins. We favor a model in which all three proteins, MEF2, myogenic bHLH protein, and E12, create a specific conformation when associated in a multiprotein complex that interacts with the transcriptional machinery more efficiently than any of the individual factors. The synergism between these factors could result from a specific recognition event between the multiprotein complex and a component of the transcriptional machinery or it could result from a concerted reaction in which the assembly of the three factors stabilizes a transcriptional complex. Previous studies with MyoD showed that its transcription activation domain was masked in solution and suggested that its exposure required the association of a cofactor that recognized the MyoD basic region (Weintraub et al., 1991) . This type of allosteric activation of MyoD by MEF2 could also account for the synergism between these factors.
MEF2 as a Coregulator of Gene Expression in Other Lineages
The ability of MEF2 to cooperate with myogenic bHLH proteins is especially intriguing because other MADS box proteins have been shown to regulate cell-specific transcription as a consequence of their interactions with positive and negative factors. MCMl , for example, acts in conjunction with two coregulators, al and a2, to regulate cell type-specific transcription in yeast (Herskowitz, 1989) , and SRF interacts with a wide range of proteins to regulate serum-inducible transcription (Shore and Sharrocks, 1995) .
The finding that MEF2 acts as a cofactor for myogenic bHLH proteins, but does not itself activate the skeletal muscle differentiation program, is consistent with the appearance of MEF2 factors in cell types other than skeletal muscle. Members of the MEF2 family are expressed at high levels, for example, in cardiac and smooth muscle cells and neurons and, as discussed above, at low levels in several other cell types. Therefore, we propose that within the skeletal muscle lineage, MEF2 acts as a potentiator of the activity of the myogenic bHLH factors, but it does not independently specify cell fate. Whether MEFP can also interact with other cell-specific bHLH proteins remains to be determined.
Experimental Procedures
Transfections and Plasmids Transfections were performed as described previously (Martin et al., 1993) . We used 10 ng of the pE102MEF2
x PCAT reporter construct (Vu et al., 1992) x 2CAT contains two MEFP sites from the MCK enhancer located upstream of the minimal promoter from the emb-MHC gene, which drives the expression of the CAT reporter gene. MEFPC deletion and point mutants will be described elsewhere (J. D. M. and E. N. O., unpublished data). The following MyoD and myogenin mutants were used. MyoD-E12basic contained the El2 basic region in place of the MyoD basic region; this mutant binds DNA, but cannot activate myogenesis (Davis et al., 1990) . MyoD-E12(AT) contains two myogenic amino acids, alanine-threonine, in place of asparagineasparagine in the basic region of MyoD-E12basrc; these residues restore myogenic activity (Davis and Weintraub, 1992) . Myogenin T67D contains an aspartic acid in place of Thr-87 in the basic region; this mutant dimerizes with E proteins, but fails to bind DNA (Brennan et al., 1991) . Myogenin bHLH, previously referred to as DM4-791136-224, lacks amino acids 4-79 and 136-224, but contains the bHLH region (Schwarz et al., 1992) . The El2 expression vector, EMSV-E12, contains a partial E72 cDNA, referred to as E12R (Murre et al., 1989) which was cloned with an initiating methionine codon into pEMSV. The EMSV-SW expression vector was a gift from M. Gilman (Ariad Pharmaceuticals).
10TYz Cell Myogenic Conversion and lmmunofluorescence To assess the ability of MEFP to convert lOT% fibroblasts into myotubes (alone or in combination with a myogenic bHLH protein), we performed transient transfections. IOTVz fibrobfasts were grown to 60% confluence in 6 cm dishes and transfected as described above with 6 pg of EMSV-MyoD (Davis et al., 1967) or EMSV-myogenin (Edmondson and Olson, 1989) and 2 ug of pCDNAI-MEFPC, when both were used together. If EMSV-MyoD was to be assessed alone, 2 ng of pCDNAl/amp vector was also included to control for possible squelching effects. If pCDNAI-MEFZC alone was to be assessed, 6 pg of EMSV plasmid was also added. After 8 hr, the cells were transferred to DMEM plus 2% horse serum (differentiation medium [DM] ) and maintained under these conditions for 6 days, with media changes occurring every 2 days. lmmunostaining for MHC was performed as described previously (Edmondson and Olson, 1989) . For MEFPC nuclear immunostaining, rabbit polyclonal MEFZC antiserum was added in blocking buffer together with the anti-myosin at a I:250 dilution. This was then detected by adding TAITC-conjugated horse, anti-rabbit antiserum at a I:400 dilution with the secondary FITC-conjugated goat, and anti-mouse antiserum. Blue nuclear staining for DNA was performed with 0.5 ug/ml of bisbenzimide in PBS for 15 min, followed by three rinses with PBS. For assessing myogenic conversion of fibroblasts to myotubes, goat anti-mouse-conjugated horseradish peroxidase (HRP) was used as the secondary antibody to allow for visual quantitation of myosin-positive cells.
Western
Blotting lOTr/z cells were transfected with MyoD, MyoD and MEFPC, MEFPC, myogenin, or myogenin and MEFPC and subjected to the same differentiation protocol as outlined above. After 6 days in DM, the cells were harvested for Western blot analysis of total MHC accumulation. The cells were lysed in 40 nl of cracking buffer (4 M urea, 0.5% SDS, 0.5% NP-40, 100 mM Tris [pH 7.41, 5 mM EDTA) and analyzed by SDS-PAGE. The primary antibody was a mouse monoclonal anti-myosin fast MY-32 (Sigma, St. Louis, MO) used at a 1:lOOO dilution. Detection was performed using the ECL kit (Amersham, Buckinghamshire, England) and required a secondary HRP-conjugated antibody (goat antimouse HRP; 1:lOOO). The results were quantitated by densitometry.
In Vitro Translations  and Coimmunoprecipitations  Interactions  between MEFPC and myogeninlE12 were assessed by immunoprecipitation of in vitro translation products myogenin and El2 with a truncated MEFPC construct (amino acids I-105). The truncated MEFPC construct contained a Flag (Kodak IBI, New Haven, CT) epitope so that anti-Flag antibody could be used for specific immunoprecipitation according to the conditions recommended by the manufacturer (Kodak IBI). The precipitated products were subjected to SDS-PAGE and autoradiography.
Tri-Hybrid
Assay To measure the ability of MEFPC to interact with the bHLH region of myogenin, we employed a tri-hybrid-like assay. C3HiOTr/z cells were maintained and transfected as described previously (Black et al., 1995) . Cells were transfected with the GALCdependent reporter plasmid pG5EI bCAT and either GAL(DBD)-Myoor GAL(DBD)-El2 to mediate binding to the GAL4 sites in the reporter. GAL(DBD)-Myo and GAL(DBD)-El2 each contain the DBD of GAL4 (amino acids 1-147) fused to either the bHLH region of myogenin or E12, respectively. We transfected 5 ng of each construct.
In transfections in which all three expression plasmids were not transfected along with the reporter, 5 ng of the appropriate parental expression plasmid was cotransfected such that in each transfection 20 ug of plasmid DNA was used. Following transfection, cells were maintained in growth medium for 24 hr and were then transferred to DM for 48 hr before harvesting. CAT assays for this analysis were performed as described elsewhere (Black et al., 1995) .
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